Brigell Mitchell

3 articles in GJC

Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension.

Brigell Mitchell, Withers Barbara, Buch Akshay, Peters Kevin G

Transl Vis Sci TechnolJan 20220 citationsClinical Trial

Razuprotafib (BID) plus latanoprost significantly lowered IOP in glaucoma/OHT patients compared to latanoprost alone, supporting Tie2 activation as a new therapeutic target for enhanced pressure control.

Full abstract PubMed

A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure.

Li Guorong, Nottebaum Astrid F, Brigell Mitchell, Navarro Iris D, Ipe Ute, Mishra Sarthak et al.

Invest Ophthalmol Vis SciDec 202042 citationsBasic Science

A Tie2 activator (AKB-9778) was studied for glaucoma. It lowered human and animal IOP by activating Tie2 in Schlemm's canal, increasing outflow. This offers a new glaucoma treatment approach.

Full abstract PubMed

Macular and Peripapillary Optical Coherence Tomography Angiography Metrics Predict Progression in Diabetic Retinopathy: A Sub-analysis of TIME-2b Study Data.

Custo Greig Eugenia, Brigell Mitchell, Cao Frank, Levine Emily S, Peters Kevin, Moult Eric M et al.

Am J OphthalmolJun 202045 citationsClinical Trial

OCTA-measured larger FAZ and reduced temporal peripapillary vessel density predict diabetic retinopathy progression. These metrics could improve DR risk assessment.

Full abstract PubMed

All 3 articles loaded

Global Search

Brigell Mitchell

Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension.

A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure.

Macular and Peripapillary Optical Coherence Tomography Angiography Metrics Predict Progression in Diabetic Retinopathy: A Sub-analysis of TIME-2b Study Data.